Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ABOS vs LGRO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABOS Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 5–3 Matrix Metrics)

ABOS Overall Winner 6-Pillar Tally: ABOS 4 – 0 LGRO (2 Tie) Matrix Metrics: ABOS 5 – 3 LGRO

As of Nov 16, 2026, Acumen Pharmaceuticals, Inc. (ABOS) is the stronger overall head-to-head candidate over Level Four Large Cap Growth Active ETF (LGRO) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ABOS carries a Unified Composite Score of 57.4/100 (HOLD) at $0.22 (N/M Forward P/E, 0.0% operating margin), whereas LGRO carries 63.4/100 (BUY) at $44.97 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While LGRO currently prints a higher short-term Unified Composite Score (63.4/100 BUY vs. ABOS 57.4/100 HOLD), ABOS captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: ABOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile LGRO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABOS vs LGRO
ABOS NASDAQ Head-to-Head Winner
Acumen Pharmaceuticals, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.22
+3.01% 1D
Market Cap $15.8M
TTM Revenue $329,000
Forward P/E N/M
Beta / 30D Vol 2.70β · 335% Vol
Unified Composite Score
57.4 / 100 HOLD
Tech 76.0 Fund 62.0 Flow 68.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.7%), weak momentum, RSI 21
RSI-14: 21.5 · SMA20: $1.00 · SMA50: $1.79
LGRO NASDAQ
Level Four Large Cap Growth Active ETF
Institutional Equity
$44.97
-2.11% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.04β · 24% Vol
Unified Composite Score
63.4 / 100 BUY
Tech 74.0 Fund 65.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.8%), weak momentum, RSI 40
RSI-14: 40.4 · SMA20: $46.33 · SMA50: $46.73

6-Pillar Scorecard Institutional Category Breakdown (ABOS 4 – 0 LGRO)

Columns: Metric · ABOS · LGRO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ABOS
Revenue Growth (YoY) +0.0% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $329,000 N/A
Market Cap $15.8M N/A
3. Profitability & Quality ABOS
Gross Margin N/A N/A
Operating Margin 0.0% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -162.7% N/A
4. Balance Sheet & Cash Flow ABOS
Cash Generation (TTM) -$105M EBITDA N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $27M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABOS
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 232.4% (41st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABOS (5) vs LGRO (3)
Institutional Metric ABOS LGRO Criterion Row Edge
Market Capitalization
Scale
$15.8M N/A Larger Scale ABOS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% N/A Higher Growth ABOS
Operating Margin (TTM)
Profitability
0.0% N/A Higher Margin ABOS
Net Profit Margin
Profitability
0.0% N/A Higher Margin ABOS
Return on Equity (ROE)
Capital Efficiency
-162.7% N/A Higher ROE ABOS
52-Week Range Position
Momentum
1% ($0–$4) 74% ($36–$48) Stronger Trend LGRO
Beta / 30D Volatility
Risk Regime
2.70β · 335% Vol 1.04β · 24% Vol Lower Realized Risk LGRO
Unified Institutional Score
Composite Signal
57.4 / 100 (HOLD) 63.4 / 100 (BUY) Higher Composite LGRO
Trailing 12M Revenue (USD)
Operating Scale
$329,000 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$105M EBITDA ($27M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LGRO +83.27 pp
ABOS: -86.95% · LGRO: -3.68%
3M Horizon LGRO +87.75 pp
ABOS: -91.95% · LGRO: -4.2%
6M Horizon LGRO +96.41 pp
ABOS: -89.89% · LGRO: +6.52%
1Y Horizon LGRO +99.22 pp
ABOS: -87.82% · LGRO: +11.4%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABOS vs LGRO. Trailing 12-month operating profitability (ABOS 0.0% vs LGRO N/A) and valuation multiples (ABOS N/M vs LGRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ABOS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$329,000
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-162.7% · N/M
LGRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABOS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 232.4%
IV Percentile 41st %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LGRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LGRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABOS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LGRO Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABOS vs LGRO Key Questions & Quantitative Answers

As of Nov 16, 2026, Acumen Pharmaceuticals, Inc. (ABOS) is the stronger overall head-to-head candidate over Level Four Large Cap Growth Active ETF (LGRO) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ABOS carries a Unified Composite Score of 57.4/100 (HOLD) at $0.22 (N/M Forward P/E, 0.0% operating margin), whereas LGRO carries 63.4/100 (BUY) at $44.97 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While LGRO currently prints a higher short-term Unified Composite Score (63.4/100 BUY vs. ABOS 57.4/100 HOLD), ABOS captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: ABOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile LGRO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABOS leads the Growth & Scale pillar: ABOS posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $329,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with LGRO at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ABOS generates $329,000 in USD-normalized revenue versus N/A for LGRO. In operating R&D and SG&A reinvestment, ABOS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LGRO.

ABOS and LGRO trade at balanced relative valuation multiples. ABOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas LGRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABOS (-162.7% ROE) versus LGRO (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ABOS carries 232.4% implied volatility (41st %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.70β · 335% Vol realized risk). By comparison, LGRO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 24% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.